Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 5/20 | 0.38 |
| ▸ | PPARA | Q07869 | 5/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12557299 | 0.92 | S1PR1 (0.39) | NPC1RAB9APPARGPPARAMAPT | |
| SCHEMBL12557305 | 0.89 | PPARG (0.41) | NPC1RAB9APPARGPPARAMAPT | |
| SCHEMBL12557289 | 0.89 | POLB (0.42) | NPC1RAB9APPARGPPARAMAPT | |
| SCHEMBL12557291 | 0.86 | RAB9A (0.47) | NPC1RAB9APPARGPPARAKDM4E | |
| SCHEMBL12557272 | 0.86 | PPARG (0.37) | NPC1RAB9APPARGPPARAMAPT | |
| SCHEMBL12557307 | 0.85 | RAB9A (0.43) | NPC1RAB9APPARGPPARAMEN1 | |
| SCHEMBL12557293 | 0.84 | S1PR1 (0.47) | NPC1RAB9APPARGPPARAMAPT | |
| SCHEMBL12557352 | 0.84 | NPC1 (0.53) | NPC1RAB9APPARGPPARAMEN1 | |
| SCHEMBL12557309 | 0.84 | NPC1 (0.40) | NPC1RAB9APPARGPPARAMEN1 | |
| SCHEMBL12557348 | 0.84 | NPC1 (0.49) | NPC1RAB9APPARGPPARASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110144374-A1 | OXIME ETHER DERIVATIVE AND FUNGICIDE FOR AGRICULTURE AND HORTICULTURE | NIPPON SODA CO., LTD. (JP) | 2011-06-16 | — | — | US | disclosed |
| US-20110144374-A1 | OXIME ETHER DERIVATIVE AND FUNGICIDE FOR AGRICULTURE AND HORTICULTURE | NIPPON SODA CO., LTD. (JP) | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144374-A1 | OXIME ETHER DERIVATIVE AND FUNGICIDE FOR AGRICULTURE AND HORTICULTURE | CBR3, CNPY2, NOX3 | NPC1 4680/4885RAB9A 4323/4885PPARG 2729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.